Tarak Srivastava
Overview
Explore the profile of Tarak Srivastava including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
100
Citations
1150
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Srivastava T, Sharma M
Glomerular Dis
. 2025 Feb;
5(1):1-12.
PMID: 39991193
Background: Minimal change disease (MCD) and focal segmental glomerulosclerosis (FSGS) are major forms of nephrotic syndrome that remain difficult to treat. MCD and FSGS have distinct but also overlapping clinical,...
2.
Panzade G, Srivastava T, Heruth D, Rezaiekhaligh M, Zhou J, Lyu Z, et al.
Cells
. 2024 Oct;
13(19.
PMID: 39404429
Chronic kidney disease (CKD) is a leading cause of morbidity and mortality globally. Maternal obesity during pregnancy is linked to systemic inflammation and elevated levels of the pro-inflammatory cytokine interleukin-6...
3.
Campbell K, Gesualdo L, Murphy E, Rheault M, Srivastava T, Tesar V, et al.
Kidney Med
. 2024 Jun;
6(6):100833.
PMID: 38831932
Rationale & Objective: Sparsentan is a novel, non-immunosuppressive, single-molecule, dual endothelin angiotensin receptor antagonist (DEARA) examined in the ongoing phase 2 DUET trial for focal segmental glomerulosclerosis (FSGS). In the...
4.
Maniar A, Gipson D, Brady T, Srivastava T, Selewski D, Greenbaum L, et al.
Pediatr Nephrol
. 2024 Apr;
39(9):2691-2701.
PMID: 38671228
Background: Steroids, the mainstay of treatment for nephrotic syndrome in children, have multiple adverse effects including growth suppression. Methods: Anthropometric measurements in children < 18 years enrolled in the Nephrotic...
5.
Schuchman M, Brady T, Glenn D, Tuttle K, Cara-Fuentes G, Levy R, et al.
J Nephrol
. 2024 Mar;
37(3):647-660.
PMID: 38512380
Introduction: The prevalence of mental health disorders including anxiety and depression is increasing and is linked to hypertension in healthy individuals. However, the relationship of psychosocial patient-reported outcomes on blood...
6.
Carboni J, Thomas E, Gipson D, Brady T, Srivastava T, Selewski D, et al.
Pediatr Nephrol
. 2024 Feb;
39(7):2161-2170.
PMID: 38319465
Background: In the current study, longitudinal BP and lipid measurements were examined in a NEPTUNE cohort of children with newly diagnosed nephrotic syndrome (cNEPTUNE). We hypothesized that hypertensive BP and...
7.
Srivastava T, Garola R, Zhou J, Boinpelly V, Rezaiekhaligh M, Joshi T, et al.
JCI Insight
. 2023 Dec;
9(3).
PMID: 38127456
Despite clinical use of immunosuppressive agents, the immunopathogenesis of minimal change disease (MCD) and focal segmental glomerulosclerosis (FSGS) remains unclear. Src homology 3-binding protein 2 (SH3BP2), a scaffold protein, forms...
8.
Riar S, Srivastava T, George R
Indian J Pediatr
. 2023 Jun;
90(12):1237-1244.
PMID: 37291387
Improvement in management of pediatric renal disorders has led to patient survival rates of 85-90%, increasing the number of adolescent and young adult (AYA) patients with childhood onset chronic kidney...
9.
Hingorani S, Gibson K, Xie Y, Wang Y, Eddy S, Hartman J, et al.
Pediatr Nephrol
. 2023 May;
38(10):3297-3308.
PMID: 37140708
Background: In single-center studies, both preterm birth and low birth weight (LBW) are associated with worse outcomes in childhood nephrotic syndrome. Using the Nephrotic Syndrome Study Network (NEPTUNE) observational cohort,...
10.
Srivastava T, Dell K, Lemley K, Gipson D, Kaskel F, Meyers K, et al.
Glomerular Dis
. 2023 Feb;
2(4):176-183.
PMID: 36817288
Introduction: Minimal change disease in childhood can follow a frequently relapsing or steroid-dependent course in up to 40% of cases. Second-line immunosuppressive medications that are used to manage these patients...